Effect of apomorphine, a dopamine receptor agonist, on penile tumescence in normal subjects

Lal, Samarthji; Ackman, Douglas; Thavundayil, Joseph; Kiely, Maureen E.; Etienke, Pierre

doi:10.1016/0278-5846(84)90040-x

Cited by 89 publications

(31 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The sexual side effects do, however, point to an enhancing effect of dopamine on sexual response, which is in line with evidence from studies in animals. In addition, there is evidence for a positive effect of bupropion, which is primarily a dopamine uptake inhibitor, on sexual functioning in women (Crenshaw and Goldberg, 1996;Segraves et al, 2004), and for a facilitating effect of apomorphine, a dopamine agonist, on sexual functioning in women with female sexual desire and arousal problems (Russell, 2002), and on erection in healthy men and in men with erectile dysfunction (Lal et al, 1984;Padma-Nathan et al, 1999). The latter resulted in the use of apomorphine in the treatment for erectile dysfunction (Giuliano and Allard, 2001;Heaton, 2000).…”

Section: Introductionmentioning

confidence: 99%

Effect of a Single Dose of Levodopa on Sexual Response in Men and Women

Both

Everaerd

Laan

et al. 2004

Neuropsychopharmacol

View full text Add to dashboard Cite

From animal research, there is ample evidence for a facilitating effect of dopamine on sexual behavior. In humans, little experimental research has been conducted on the inter-relation between dopamine and sexual response, even less so in women than in men. We investigated the effect of levodopa (100 mg) on sexual response in men and women following a double-blind, placebo-controlled crossover design. Genital and subjective sexual responses were measured as well as somatic motor system activity by means of Achilles tendon (T) reflex modulation. Genital and subjective sexual arousal were not affected by levodopa. However, the drug increased T reflex magnitude in response to sexual stimulation in men, but not in women. These results support the view that dopamine is involved in the energetic aspects of appetitive sexual behavior in men. The observed gender difference in the effect of levodopa is discussed in the perspective of possible dopamine-steroid interaction.

show abstract

Section: Introductionmentioning

confidence: 99%

Effect of a Single Dose of Levodopa on Sexual Response in Men and Women

Both

Everaerd

Laan

et al. 2004

Neuropsychopharmacol

View full text Add to dashboard Cite

show abstract

“…As a parallel to this clinical studies have tried to show the therapeutic properties of drugs administered to men suffering from impotence (Laln et al, 1987b;Reid et al, 1987). Dopaminergic agonists, in particular apomorphine, induce erection in animals (Ferrari et al, 1985;Foreman & Hall, 1987) and in man (Lal et al, 1984(Lal et al, , 1987a.…”

Section: Introductionmentioning

confidence: 99%

Assessment of erectogenic properties of apomorphine and yohimbine in man.

Danjou

Alexandre

Warot

et al. 1988

Brit J Clinical Pharma

View full text Add to dashboard Cite

1 In a fourperiod, double-blind, placebo-controlled study, apomorphine (0.009mg kg-1 subcutaneous route) and yohimbine (0.30 mg kg-' i.v. route) were administered to 10 male healthy volunteers. Penile circumference was monitored using plethysmography and subjective sexual arousal was self-assessed. Data were collected before, during and after a stimulation session during which 50 erotic slides were projected to the subjects. 2 Apomorphine induced an erection starting from the fourth minute post-injection, and potentiated the visually-induced response. Self assessment showed increased tumescence and rigidity without modifications of sexual arousal. 3 Yohimbine did not modify penile diameter without stimulation and did not affect the physiological response to erotic stimuli. 'Sexual excitement' was decreased by yohimbine during the post-stimulation phase. One subject experienced severe anxiety while he was infused with yohimbine. 4 These results are discussed with reference to animal data and to recent studies carried out in impotent patients.

show abstract

“…[20][21][22][23] It is degraded by the first-pass metabolism, so must be taken via injection, sublingually, or via a nasal spray formulation. The drug is not approved in the United States for an ED indication, but is available in the European Union.…”

Section: Dopaminergic Agentsmentioning

confidence: 99%

Clinical applications of centrally acting agents in male sexual dysfunction

Hellstrom

2008

Int J Impot Res

View full text Add to dashboard Cite

Currently available agents for erectile dysfunction (ED) share the same mechanism of action and pharmacologic properties. Therefore, they share the same limitations, including a principal focus on erection as an end-organ process. One of the relatively unexplored areas of research has been the potential for centrally acting agents to improve male sexual response. A variety of neurohormones and neurotransmitter systems are involved in the male sexual response, including testosterone, dopamine, serotonin and the melanocortin systems. Investigations to determine the utility of centrally acting agents as monotherapy or adjunctive therapy in men with ED or other forms of sexual dysfunction are underway. Bremelanotide, a melanocortin agonist, has been tested in men with ED and may prove to be one of the first centrally acting agents to have clinical utility in male sexual dysfunction.

show abstract

Effect of apomorphine, a dopamine receptor agonist, on penile tumescence in normal subjects

Cited by 89 publications

References 16 publications

Effect of a Single Dose of Levodopa on Sexual Response in Men and Women

Effect of a Single Dose of Levodopa on Sexual Response in Men and Women

Assessment of erectogenic properties of apomorphine and yohimbine in man.

Clinical applications of centrally acting agents in male sexual dysfunction

Contact Info

Product

Resources

About